Mascarenhas, Leo

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 2,824

Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 1,028

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Smeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D., Gorlick, R., Janeway, K. A., Ingleby, F. C., Anninga, J., et al. (2019) · European Journal of Cancer

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 704

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 551

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., et al. (2019) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 268

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group

Shulman, D. S., Klega, K., Imamovic-Tuco, A., Clapp, A., Nag, A., Thorner, A. R., Van Allen, E., Ha, G., Lessnick, S. L., Gorlick, R., et al. (2018) · British Journal of Cancer

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 149

Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors

Christodoulou, E., Yellapantula, V., O’Halloran, K., Xu, L., Berry, J. L., Cotter, J. A., Zdanowicz, A., Mascarenhas, L., Amatruda, J. F., Ostrow, D., et al. (2023) · npj Precision Oncology

Cancer Genomics and DiagnosticsSarcoma Diagnosis and Treatment

Cited by 55

Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study.

Shulman, D. S., Klega, K. S., Chen, N., Gohn, E., Henry, D., Choy, E., Cash, T., Schultz, K. A. P., Mascarenhas, L., Bagatell, R., et al. (2024) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 8